DC 20231.



Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents.

Practitioner's Docket No. MPI00-557P1RM **PATENT** Certificate of Transmission under 37 CFR 1.8 I hereby certify that this correspondence is being facsimile transmitted to the **United States Patent and Trademark Office** FAX RECEIVED on April 14, 2003. APR 15 2003 GROUP 1600 Mary MacKinnon Typed or printed name of person signing Certificate Note: Each paper must have its own certificate of transmission, or this certificate must identify! each submitted paper. Submitted herewith: (2 pages) Transmittal Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney from Millennium Pharmaceuticals, Inc. (2 pages) Change of Attorney Docket Number (1 page) **Total Pages** (6 pages) (including this cover sheet)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chiang Lillian Wei-Ming, et al.

Application No.:

10/047,855

Group:

Not Assigned

Filed:

January 15, 2002

Examiner:

Not Assigned

For:

NARCIO AND NARCIO, PROGRAMMED CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

Commissioner for Patents Washington, D.C. 20231

#### TRANSMITTAL

- Transmitted herewith for this application is/are: 1.
  - This Transmittal (2 pages);
  - Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney (2 Ь. pages);
  - Change of Attorney Docket Number (1 page). C.

#### **STATUS**

2. Applicant is other than a small entity.

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail. as "Express Mail Post Office to Address"

Mailing Label No.

**TRANSMISSION** œ transmitted by facsimile to the Patent and Trademark Office.

Signature

April 14, 2003 Date: \_\_\_

Mary MacKinnon

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)



## FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.

April 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

′ \_\_\_

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139 Telephone - 617-761-6865 Facsimile - 617-551-8820



**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chiang, Lillian Wei-Ming, et al.

Application No.:

10/047,855

Group:

Not Assigned

Filed:

January 15, 2002

Examiner:

Not Assigned

For:

NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

Commissioner for Patents Washington, D.C. 20231

# REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on <u>June 4, 2002</u>, at Reel <u>012959</u>, Frame <u>0349</u> hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

	CERTIFICATION UNDER 3	7 C.F.R. SECT	TIONS 1.8(a) and 1.10*		
I hereby	certify that, on the date shown below, this correspon	ndence is being:			
	ת	MAILING			
	deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents,				
	Washington, D.C. 20231.				
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*		
0	with sufficient postage as first class mail.		as "Express Mail Post Office to Address" Mailing Label No.		
	TRA	NSMISSION			
	transmitted by facsimile to the Patent and Tradema	ark Office. Signa	we Man Malkenn		
Date: _	April 14, 2003		MacKinnon or print name of person certifying)		

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945, Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to Paul J. Paglierani at 617-761-6865.

MILLENNIUM PHARMACEUTICALS, INC.

Ву: _		us milier	
Typed	Name.	ean M. Silveri	
Title:	Associa	ate General Counsel	
Dated	: April 1	14, 2003	

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chiang, Lillian Wei-Ming, et al.

Application No.:

10/047.855

Group:

Not Assigned

Filed:

January 15, 2002

Examiner:

Not Assigned

For:

NARC10 AND NARC16, PROGRAMMED

CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

**Commissioner for Patents** Washington, D.C. 20231

# **CHANGE OF ATTORNEY DOCKET NUMBER**

Dear Sir:

Please note that the Attorney Docket Number has been changed from

35800/242056(5800-190) to MPI00-557P1RM. Please reference MPI00-557P1RM on all future correspondence.

Respectfully submitted,

April 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

Paul J. Paglierani

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820

# CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail. as "Express Mail Post Office to Address"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: <u>April 14, 2003</u>

×

Mary MacKinnon

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)

Vaclinas